News|Videos|December 4, 2024

Transforming “what if” to “what is” with the Veradigm Network

Our network connects providers, health plans, and life science companies to deliver seamless care that benefits everyone


Related to this article

Pharmaceutical Executive Daily
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.